Clinical Cancer Research
@CCR_AACR
Followers
8K
Following
843
Media
3K
Statuses
7K
Follow Clinical Cancer Research for innovative clinical trials and precision medicine. Published by @AACR.
Joined July 2018
A series of papers in @CCR_AACR shared important considerations for improving dosage optimization in oncology. Visit the #AACRBlog for an overview of the insights provided on selecting dosages that maximize both safety and efficacy:
aacr.org
A series published in the AACR journal Clinical Cancer Research shared key considerations for improving dosage optimization in oncology.
0
1
4
➡️Selecting Optimized Dosages for Registrational Trials https://t.co/AxbfoIWyHr Successful applications of innovative trial designs and model-based approaches to aid the selection of better optimized dosages for evaluation in registrational clinical trials.
aacrjournals.org
Abstract. The maximum tolerated dose has historically been the recommended phase two dose, and this dosage has typically been evaluated in registrational clinical trials for oncology drugs. With the...
0
1
0
➡️Early Phase Trials Using Innovative Trial Designs and Biomarkers https://t.co/IEHMCoSsQl Areas for further development regarding innovative techniques for the selection of dosages for further evaluation prior to final dosage selection for registrational trials in oncology.
aacrjournals.org
Abstract. Dosage selection for oncology drugs has traditionally relied on initial dose-finding trials to determine a maximum tolerated dose (MTD), which is then further evaluated in approval-suppor...
1
1
1
➡️Selecting Dosages for First-In-Human Trials https://t.co/IEHMCoT0FT Suggestions for the future of dosage selection and optimization in FIH oncology trials.
aacrjournals.org
Abstract. Dosage selection for oncology drugs has traditionally relied on initial dose-finding trials to determine a maximum tolerated dose (MTD), which is then further evaluated in approval-suppor...
1
1
0
#OnlineFirst Perspectives in Regulatory Science and Policy— FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products Check out this series of three papers discussing innovative strategies for dosage optimization.
1
2
4
Phase 1b Study: Pembrolizumab + Clostridium novyi-NT in Patients with Advanced Solid Tumors. https://t.co/3ZFaJsmKef
0
0
3
Read the September Editors' Picks: Cemiplimab for Secondary Angiosarcomas https://t.co/GY3VVmPl2R Tarlatamab in Neuroendocrine Prostate Cancer
aacrjournals.org
AbstractPurpose:. Neuroendocrine prostate cancer (NEPC) is an aggressive form of prostate cancer with poor prognosis and limited treatment options. As NEPC aberrantly expresses delta-like ligand 3...
This month, the editors of the 10 AACR journals have highlighted studies on brain cancer detection and factors influencing immunotherapy efficacy. Read about the September Editors’ Picks on the #AACRBlog: https://t.co/yMANavC2qQ
0
2
2
Phase 1b Study (DeLLpro-300): Tarlatamab in Patients with Neuroendocrine Prostate Cancer. https://t.co/bfVbvm3DNS
0
0
5
Read the latest editors' picks: https://t.co/LxcncJyYqx Stay up to date with the @AACR journals by signing up for alerts: https://t.co/Rw4RMHMqgy
0
0
3
Read the Clinical Cancer Research Pediatric Oncology article series. https://t.co/UHbCDUFak5
#AACRpediatric25
0
1
5
Joseph C. Murray, MD, PhD, recipient of the 2025 Clinical Cancer Research Early Career Award, speaks about the questions that drive his research in the clip below. To learn more, watch the full interview: https://t.co/MfUZQGPh66
@HopkinsMedicine @hopkinskimmel
0
0
5
Clinical Cancer Research publishes innovative, high-impact clinical trials. Read the recently updated article collection: https://t.co/8D8lGQIhh3
0
0
6
Stop procrastinating. Snap to get things done before it gets cold. 🐊 @getdelegator to make tasks fun (and done).
2
3
6
Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study: https://t.co/UcVN5SfljD
#AACRovca25
0
0
4
Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice: https://t.co/nlIBBuppEl
#AACRovca25
0
3
12
Chemotherapy Drives Tertiary Lymphoid Structures That Correlate with ICI-Responsive TCF1+CD8+ T Cells in Metastatic Ovarian Cancer: https://t.co/klBBX6ekvM
#AACRovca25
0
1
9
OvaPrint—A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer: https://t.co/sgonFgBDrU
#AACRovca25
0
0
6
Do you support calling Congress back into session to have a vote on releasing the Epstein files?
0
0
5
Neoadjuvant Chemotherapy with Dual Immune Checkpoint Inhibitors for Advanced-Stage Ovarian Cancer: Final Analysis of TRU-D Phase II Nonrandomized Clinical Trial: https://t.co/wL8jpQlmdX
#AACRovca25
0
1
5
Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities: https://t.co/deIZLWv41c
#AACRovca25
0
0
4
SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer: https://t.co/jp0qETzDKG
#AACRovca25
0
0
3